Document is current

Article History

Received: 18 May 2021

Accepted: 16 June 2021

First Online: 28 August 2021

Declarations

:

: The study was approved by the Research Ethics Committees of participating centers in Switzerland and the U.K. The study was conducted in full accordance with the principles of the World Medical Association Declaration of Helsinki, the International Conference of Harmonisation, and all applicable local guidelines and regulations on good clinical practice.

: All patients provided written informed consent to participate in this study.

: All patients provided written informed consent about participation in this study and the use of collated data. No individual patient data are included in this article that could be used to identify any individual.

: Yannis Metaxas received institutional grant for clinical trials from PharmaMar S.A. and Bristol-Meyers Squibb; travel grant from PharmaMar S.A.; and advisory board from PharmaMar S.A.. Carmen Kahatt, Vicente Alfaro, Salvador Fudio and Ali Zeaiter are employees and stock owners of Pharma Mar, S.A. Ruth Plummer received fees as advisory board member from Pierre Faber, Bayer, Novartis, Biosceptre, BMS, Cybrexa, Ellipses, CV6 Therapeutics, Astex Therapeutics, Medivir, GammaDelta Therapeutics, and Sanofi Aventis. Roger von Moos received fees as advisory board member for Astra Zeneca, BMS, Celgene, MSD, Pierre Fabre, Pharmamar S.A., Polyphor, Roche, Vifor, and speaker honoraria from Amgen. Martin Forster received research funding (institutional) from AstraZeneca, Boehringer Ingelheim, MSD and Merck and conducted consulting and advisory services, speaking or writing engagements, or public presentations for Achilles, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Guardant Health, Merck, MSD, Nanobiotix, Novartis, Oxford VacMedix, Pfizer, PharmaMar, S.A. Roche and Takeda. Anastasios Stathis received Institutional grants for clinical trials from PharmaMar S.A., Merck, Bayer, Roche, Novartis, Pfizer, ADC Therapeutics, MEI Pharma and Eli Lilly; advisory board from Roche and Janssen; consultant fees from Bayer and Eli Lilly. Other authors declared no conflict of interest/competing interests.